Zai Lab Limited (ZLAB) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.75: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Zai Lab is a commercial-stage global biopharma with substantial operations in Greater China focused on oncology, immunology, neuroscience, and infectious disease, with 7 commercially launched products including ZEJULA, VYVGART, NUZYRA, and AUGTYRO. Revenue is generated from... Read more
Sell if holding. Engine safety override at $18.75: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Score 5.0/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Zai Lab Limited
Latest news
- UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session — benzinga May 18, 2026 neutral
- The FDA Grants Fast Track Designation To Zai Lab's Zocilurtatug Pelitecan (Zoci, formerly ZL-1310) for Extrapulmonary Ne — benzinga May 11, 2026 positive
- Citigroup Maintains Buy on Zai Lab, Lowers Price Target to $44 — benzinga May 8, 2026 neutral
- Zai Lab Q1 EPS $(0.46) Beats $(0.54) Estimate, Sales $99.611M Miss $108.450M Estimate — benzinga May 7, 2026 neutral
- Reported Earlier, Zai Lab Announced New Data From A Preclinical Study Of ZL-1503, Demonstrating That The Company's Inter — benzinga Apr 20, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicmainland China (all commercial operations)10-K Item 1A: 'A substantial portion of our operations, and all of our commercial operations, are conducted in mainland China'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Unprofitable operations — net margin -38.1%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.75: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Prior stop was $17.67. Score 5.0/10, moderate confidence.
Take-profit target: $29.75 (+61.9% upside). Prior stop was $17.67. Stop-loss: $17.67.
Concentration risk — Geographic: mainland China (all commercial operations); Quality below floor (2.0 < 4.0).
Zai Lab Limited trades at a P/E of N/A (forward -11.1). TrendMatrix value score: 8.3/10. Verdict: Sell.
14 analysts cover ZLAB with a consensus score of 3.9/5. Average price target: $34.
What does Zai Lab Limited do?Zai Lab is a commercial-stage global biopharma with substantial operations in Greater China focused on oncology,...
Zai Lab is a commercial-stage global biopharma with substantial operations in Greater China focused on oncology, immunology, neuroscience, and infectious disease, with 7 commercially launched products including ZEJULA, VYVGART, NUZYRA, and AUGTYRO. Revenue is generated from in-licensed product sales across mainland China, Hong Kong, and Macau via NRDL inclusion and supplemental insurance coverage.